20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Sanofi SA (NASDAQ:SNY) said it would stop further work on breast cancer drug amcenestrant, putting pressure on Sanofi to bolster its drug development pipeline as it grows increasingly dependent on its best-seller, eczema and asthma treatment Dupixent.
- A trial dubbed AMEERA-5, which was testing amcenestrant on women with newly-diagnosed advanced breast cancer was stopped early because an independent monitoring panel found no signs of it working. "All other studies of amcenestrant, including in early-stage breast cancer (AMEERA-6), will be discontinued," Sanofi said.
- No new safety signals were observed. Trial participants will be transitioned to letrozole in combination with palbociclib or another appropriate standard of care therapy, as determined by their physician.
- In March, Sanofi announced disappointing results of a breast cancer study involving previously treated women.
- Sanofi said the drug, which was used with Pfizer's Inc's (NYSE:PFE) Ibrance (palbociclib) in the study, "did not meet the prespecified boundary for continuation" when compared to a group of patients in the trial on standard hormone therapy.
- Amcenestrant belongs to a drug class known as selective estrogen receptor degraders (SERD) to fight tumors that grow in response to estrogen.
- Price Action: SNY shares are down 6.40% at $41.94 during the premarket session on the last check Wednesday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!